|Home | About | Journals | Submit | Contact Us | Français|
The Quick Environment Exposure Sensitivity Inventory (QEESI©) has been used as a questionnaire to evaluate subjective symptoms of patients with multiple chemical sensitivity (MCS), also known as idiopathic environmental intolerance, in Japan. However, no cutoff value for Japanese subjects has yet been established. We designed this study to establish a cutoff value for Japanese subjects using QEESI© for screening of MCS patients.
A questionnaire using the QEESI© was administered to 103 MCS patients and 309 healthy control subjects matched for age and sex. QEESI© scores of the two groups were compared using logistic regression analysis, receiver operating characteristic analysis, and the Mann–Whitney test.
Cutoff values for Japanese subjects were determined for the Chemical Intolerance subscale (40), Symptom Severity subscale (20), and Life Impact subscale (10). The subjects whose scores exceeded the cutoff values in any two subscales accounted for 88.4% of the patients but only 14.5% of the controls.
Our results suggest that subjects meeting two out of three subscale criteria can be screened as “patients suffering from a low level of environmental chemicals such as MCS” in Japan.
Multiple chemical sensitivity (MCS) is the term most commonly used to describe a disorder which is characterized by a broad array of physical, psychological, and emotional symptoms, the cause of which is attributed to exposure to extremely low levels of a wide variety of environmental chemicals . MCS, also known as idiopathic environmental intolerance (IEI), is a syndrome which progresses to multiple organ dysfunction, mainly involving the autonomic nervous system, with extremely low-level chemical exposure [2–10]. However, the pathogenesis and underlying mechanisms have not been fully clarified anywhere in the world, and internationally unified diagnostic criteria for MCS have not been established . At present, there are at least seven case definitions for MCS, including those of Randolf , Cullen , Nethercott , and the 1999 Consensus in the USA , but no case definition has been proven worldwide. Among them, the 1999 Consensus is considered the most comprehensive and well-known case definition, and is now being used in the USA, Germany, and a number of other countries . In Japan, however, the only diagnostic standard currently in use for MCS is the diagnostic guideline proposed in 1998 by the Allergy Research Study Project of the Ministry of Health, Labor, and Welfare . Various objections have been raised to each of these different standards, however, and there is still much room for further debate on this issue.
Given this situation, we considered that the most effective way to establish a reliable diagnostic standard for MCS in Japan would be to identify the characteristic features of Japanese MCS patients, and then to undertake a detailed analysis of a group of these patients selected according to a diagnostic standard that would allow comparison with results from other countries.
In the USA, Miller and Prihoda [17, 18] developed a globally standardized self-administered questionnaire, the Quick Environment Exposure Sensitivity Inventory (QEESI©), which was designed to assist researchers and clinicians in screening, studying, and evaluating patients for MCS. QEESI© is a questionnaire recommended in the 1999 Consensus mentioned above. The Japanese version of QEESI© was translated by Ishikawa and Miyata . We  surveyed the reliability and validity of the QEESI© (Japanese version) in the Japanese population and concluded that 30 questions of three subscales in the QEESI© (Chemical Intolerance, Symptom Severity, and Life Impact) showed high reliability and validity that allowed comparison between MCS patients in Japan and those in other countries. However, Other Intolerance, the fourth QEESI© subscale, showed small factor loading with random scattering. Therefore, we concluded that this subscale is not useful in Japan and that revision of this subscale is thus required for more accurate assessment of Japanese patients .
Additionally, we  conducted a questionnaire survey using the QEESI© (Japanese version) in 498 Japanese subjects not previously diagnosed as having MCS, and 17 subjects were consequently identified as having clinical features consistent with “very suggestive of MCS” based on the criteria of Miller and Prihoda (Chemical Intolerance ≥40 and Symptom Severity ≥40) . In accordance with our recommendation, 7 of the 17 subjects participated in a medical examination and were diagnosed as having MCS by expert physicians of the Environmental Medical Center, Kitasato Institute Hospital, suggesting the QEESI© (Japanese version) to be useful for screening MCS patients in Japan . However, we  also compared QEESI© scores between Japanese MCS patients and the American MCS patients reported by Miller and Prihoda . We found the scores of the Japanese MCS patients to be considerably lower than those of the American MCS patients, indicating that a unique Japanese cutoff value is necessary to screen Japanese MCS patients.
Therefore, we designed this study to establish a cutoff value for Japanese subjects using QEESI© for the screening of MCS patients.
The subjects were 103 patients (24 males with mean age of 36.2 ± 9.9 years and 79 females with mean age of 42.9 ± 13.8 years) who visited the Outpatient Division of the Environmental Medical Center, Kitasato Institute Hospital during the 3-year period from March 2001 to March 2004. They met the 1999 Consensus (US)  and the Japanese diagnostic criteria for MCS , had been diagnosed as having MCS by three specialists, and had also completed the QEESI© questionnaire. The symptoms associated with MCS have similarities to chronic fatigue syndrome (CFS), fibromyalgia (FM), and psychological disorders . Therefore, patients who had been diagnosed by a doctor as having chronic fatigue syndrome or fibromyalgia syndrome were excluded from the study. In addition, patients suspected of having psychological disorders were examined by a qualified psychiatrist or practitioner of psychosomatic medicine, and those patients diagnosed with mental health disorders based on DSM-III or ICD-10 were also excluded from the study.
The controls were 309 healthy people matched for age and sex with the MCS patient group (72 males and 227 females). We sent a QEESI© (Japanese version) and a general health questionnaire [asking about current health status (good/bad), whether the subject had been diagnosed with a disease by a physician, and if so, the name of the disease, etc.], to 4,000 members of the general public who belonged to universities, architect groups, and cooperative societies in 26 prefectures in Japan, including Hokkaido, Miyagi, Kanagawa, Tochigi, Saitama, Tokyo, Nagano, Oita, and Aichi, from April 2003 to March 2005.
A total of 2,564 responses were received, and after excluding incomplete responses, 2,500 were determined to be valid. Subjects who reported by themselves that they were unhealthy or had been diagnosed with any disease by a doctor [MCS, sick house syndrome (SHS), diabetes, mental disorders including depression, etc.] were further excluded. A sex- and age-matched (±5 years; N = 309) control group was randomly selected from the remaining 1,857 subjects.
All 103 MCS patients underwent the three neuro-ophthalmologic examinations (smooth pursuit eye movement, contrast sensitivity function, and pupillary reaction to light) included in the Japanese MCS diagnostic criteria, as well as general neurological and electrocardiographic examinations described previously [21, 23]. Each of these tests is used in the diagnosis of diseases other than MCS. The normal range was determined by evaluating data from a large number of healthy Japanese, and those whose results fell outside the normal range were diagnosed as abnormal [21, 23].
In this study we used 30 items in three subscales (Chemical Intolerance, Symptom Severity, and Life Impact) of QEESI© outlined below (Table 1). The MCS patients and control subjects had completed the QEESI©.
This scale was comprised of ten common chemical inhalants that represent structurally diverse classes of chemicals to which MCS patients frequently attribute their symptoms : diesel or gas engine exhaust (petrochemical combustion products), tobacco smoke, insecticide (pesticides), gasoline vapors (fuels), paints or paint thinner (solvents), cleaning products such as disinfectants or bleach (structurally diverse clearing agents), fragrances, fresh tar or asphalt (polynuclear aromatics), nail polish, nail polish remover or hairspray, new furnishings such as carpets (fragrance/solvent), and soft plastic shower curtains or the interior of new cars (solvents, plasticizers, formaldehyde). Each item includes a 0–10 rating scale, the ratings being tallied to obtain a total scale score of 0–100. Miller and Prihoda  defined the criteria for three levels of symptom score as low (0–19), medium (20–39), and high (40–100).
The ten items on this scale were derived via factor analysis of responses to 114 symptoms used in a study of 112 IEI patients who were exposed to either pesticides or indoor contaminants . Items include musculoskeletal, airway/mucous membrane, heart/chest-related, gastrointestinal, cognitive, affective, neuromuscular, head-related, skin, genitourinary, and symptoms. Each item includes a 0–10 rating scale, summed to obtain a total score of 0–100. Miller and Prihoda  defined the criteria for three levels of symptom score as low (0–19), medium (20–39), and high (40–100).
Respondents rated the degree to which chemical or food sensitivities adversely impacted each of ten aspects of their lives: diet, ability to work or attend school, choice of home furnishings, choice of clothing, ability to drive or travel, choice of personal care products such as cosmetics or deodorants, ability to be around others and enjoy social activities, choice of hobbies or recreation, relationships with spouse and family, and ability to perform household chores. Each item includes a 0–10 rating scale, summed to obtain a total score of 0–100. Miller and Prihoda  defined the criteria for three levels of symptom score as low (0–11), medium (12–23), and high (24–100).
In order to statistically analyze subjective symptoms of the MCS patient group and the control group, we compared the QEESI© scores of 30 items in three subscales (Symptom Severity, Chemical Intolerance and Life Impact) by logistic regression analysis and receiver operating characteristics (ROC) analysis using SPSS version 13 for Windows.
This study was approved by the Human Ethics Committee of the Environmental Medical Center of Kitasato Institute Hospital, and all participants gave written informed consent. No individual names or other data allowing identification of participants were included in the database.
Figure 1 shows the frequency distribution of the total points for three subscales in the QEESI© (Symptom Severity, Chemical Intolerance, and Life Impact). While the control group showed an ever-decreasing distribution, with the highest frequency being that of 0 in all three subscales, the MCS patient group showed a widely scattered distribution. However, high scores, 40 points or more, for Chemical Intolerance were relatively common in the control group as well.
We performed ROC analysis to briefly screen the MCS patients using the QEESI© (Fig. 2). The cutoff value was set when the total for sensitivity and specificity reached the maximum, i.e., 40 points for Chemical Intolerance, 20 for Symptom Severity, and 10 for Life Impact. Symptom Severity had the highest discrimination ability, showing a sensitivity of 84.8%, specificity of 84.0%, and ROC area under the curve of 0.935. Life Impact also had high discrimination ability, showing a sensitivity of 84.8%, specificity of 85.7%, and ROC area under the curve of 0.928. However, for the Chemical Intolerance subscale, sensitivity, specificity, and ROC area under the curve had low discrimination abilities (73.4, 69.6, and 0.779%, respectively) compared with the other two subscales.
Figure 3 shows the distribution of subjects in the MCS patient group and the control group by classification using the cutoff values provided above. The number of subjects for whom the three circles at Chemical Intolerance ≥40, Symptom Severity ≥20, and Life Impact ≥10 overlapped was 62 (60.2%) in the MCS patient group and 10 (3.2%) in the control group. Furthermore, 88.4% of the MCS patient group, but only 14.5% of the control group, reached or exceeded the cutoff value in any two of the three subscales (Fig. 3).
Mean scores in all 30 items for the MCS patients were significantly higher than those for controls (Fig. 4a–c). However, there were no differences in the radar chart patterns of Chemical Intolerance and Symptom Severity between the MCS patients and the controls. The radar chart pattern of the Life Impact subscale differed somewhat between the two groups. The peaks were in “ability to work,” “choice of home furnishings,” “choice of personal care products,” and “social activity,” while the scores for “diet” and “relationships with spouse and family” were relatively low in the MCS patient group.
In order to study the discrimination abilities of all subjective symptoms, we performed logistic regression analysis for a total of 30 items in the three subscales of Chemical Intolerance, Symptom Severity, and Life Impact (Table 1).
The odds ratio was 1.32–1.57. The differences among individual items were small. The odds ratios, in descending order, were as follows: “nail polish or hairspray” (1.57) > “new furnishings” (1.56) > “fragrances” (1.52) > “cleaning products” (1.51) > “paint or paint thinner” (1.43).
The odds ratio was 1.46–1.95 and exceeded 1.5, except for “skin” (1.46). In particular, the odds ratios for the following items were more than 1.7, showing high discrimination ability: “cognitive” (1.95) > “airway/mucous membranes” (1.90) > “heart/chest-related” (1.88) > “head-related” (1.86) > “neuromuscular” (1.84) > “affective” (1.75).
The odds ratio was 1.51–2.74, the highest of the three subscales. In particular, the odds ratio was 1.8 or more for “ability to work or attend school” (2.74) > “ability to be around others and enjoy social activities” (2.66) > “choice of hobbies or recreation” (2.31) > “choice of home furnishings” (2.03) > “diet” (1.92) > “ability to perform household chores” (1.86). Furthermore, the odds ratio was high for MCS-specific impairment, which was not seen in other diseases, including “choice of home furnishings” (2.03) and “choice of personal care products” (1.70).
In this study, we performed a questionnaire survey using the QEESI© in clinically diagnosed patients with MCS, also known as IEI, and healthy individuals matched for age and sex, in order to set a unique cutoff value for screening of MCS patients in Japan. We determined unique Japanese cutoff values for the Chemical Intolerance subscale (40), Symptom Severity subscale (20), and Life Impact subscale (10). The subjects whose scores met or exceeded the cutoff values in any two of the three subscales accounted for 88.4% of the patient group but only 14.5% of the control group. Our results suggest that subjects meeting two of the three criteria can be screened as “suspected of having MCS” in Japan. In comparing the above-mentioned Japanese cutoff values with those developed by Miller and Prihoda in the USA , we found Chemical Intolerance to have the same cutoff value in Japan and the USA, while the cutoff value for Symptom Severity in Japan was about half that in the USA . These results may be attributable to the frequency distribution of Symptom Severity in MCS patient groups in the USA being limited to within a high score range, while scores of the Japanese MCS patients were widely distributed from low to high. There were no significant differences between the control groups in Japan and the USA.
Another difference from US results was that we did not examine the Other Intolerance subscale in QEESI© to evaluate the effects of chemical exposures from foods, etc., because the results of factor analysis for this subscale had previously been reported to be inconsistent with those reported by Miller and Prihoda . Furthermore, ROC analysis also showed low sensitivity (69.9%), low specificity (54.7%), and low area under the ROC curve (0.692) in this study. Therefore, we concluded that the Other Intolerance subscale should be excluded when applying the QEESI© to evaluate subjective symptoms of MCS patients in Japan. Instead, we used the Life Impact subscale, which had high discrimination ability, the same as that of the Symptom Severity subscale.
We reconfirmed in this study that the QEESI© is effective for screening of Japanese MCS patients, and obtained optimal cutoff values. However, the definition of MCS is still under discussion. Recently, a scientific review of MCS in Australia  stated that several primary research needs are evident, including the establishment of agreed diagnostic criteria that are acceptable to clinical and scientific groups. The QEESI© is at least useful to screen patients who are suffering from a low level of environmental chemicals such as in MCS and thus to help establish the clinical definition of MCS.
QEESI© is also used in other countries such as the USA, Germany, Taiwan, and Korea, so it is an effective means of comparing subjective symptoms among patients in different countries. Moreover, unlike conventional questionnaires which ask only for “yes” or “no” responses, QEESI© asks subjects to evaluate their subjective condition on a scale of 0–10, making it possible to perform certain quantitative analyses as well as effectiveness of treatments, multivariate analysis to clarify clinical condition, etc.
In the future, we will conduct further questionnaire surveys using the QEESI©, targeting the general population, with randomly selected and distinct groups of MCS as well as patients with other diseases such as sick house syndrome, allergies and mental disorders including depression.
The authors are grateful to Prof. Yoshiharu Aizawa for his valuable assistance. This study was supported in part by grants-in-aid for scientific research (Hojo C 19510074), JSPS, Japan and a grant-in-aid for scientific research subsidized by the Ministry of Health, Labor, and Welfare and by the Long-range Research Initiative of the Japan Chemical Industry Association.